James M Ferguson

Summary

Publications

  1. ncbi request reprint An open-label, flexible-dose study of memantine in major depressive disorder
    James M Ferguson
    Department of Psychiatry, University of Utah School of Medicine, USA
    Clin Neuropharmacol 30:136-44. 2007
  2. ncbi request reprint Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release
    James M Ferguson
    University of Utah School of Medicine, Psychiatry, Salt Lake City, UT 84103, USA
    J Clin Psychiatry 68:58-68. 2007
  3. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
  4. doi request reprint High-dose desvenlafaxine in outpatients with major depressive disorder
    James M Ferguson
    University of Utah School of Medicine, Salt Lake City, UY, USA
    CNS Spectr 17:121-30. 2012
  5. ncbi request reprint Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
    James M Ferguson
    University of Utah, Salt Lake City, Utah, USA
    Int Clin Psychopharmacol 18:9-14. 2003
  6. ncbi request reprint Citalopram treatment of paroxetine-intolerant depressed patients
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute Clinic, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
    Depress Anxiety 16:128-33. 2002
  7. ncbi request reprint The antidepressant efficacy of reboxetine in patients with severe depression
    Stuart Montgomery
    Imperial College School of Medicine, London, U K
    J Clin Psychopharmacol 23:45-50. 2003
  8. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
  9. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    J Clin Psychiatry 68:1246-56. 2007
  10. ncbi request reprint Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder
    Anita H Clayton
    University of Virginia, Department of Psychiatric Medicine, Charlottesville 22903, USA
    Int Clin Psychopharmacol 18:151-6. 2003

Detail Information

Publications10

  1. ncbi request reprint An open-label, flexible-dose study of memantine in major depressive disorder
    James M Ferguson
    Department of Psychiatry, University of Utah School of Medicine, USA
    Clin Neuropharmacol 30:136-44. 2007
    ..To assess the efficacy and safety of flexible-dose memantine in patients with major depressive disorder (MDD)...
  2. ncbi request reprint Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release
    James M Ferguson
    University of Utah School of Medicine, Psychiatry, Salt Lake City, UT 84103, USA
    J Clin Psychiatry 68:58-68. 2007
    ..To compare the long-term efficacy of venlafaxine extended release (ER) with placebo in preventing panic disorder relapse in out-patient treatment responders...
  3. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
    ..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
  4. doi request reprint High-dose desvenlafaxine in outpatients with major depressive disorder
    James M Ferguson
    University of Utah School of Medicine, Salt Lake City, UY, USA
    CNS Spectr 17:121-30. 2012
    ..This study investigated the safety and efficacy of long-term treatment with high-dose desvenlafaxine (administered as desvenlafaxine succinate) in major depressive disorder (MDD)...
  5. ncbi request reprint Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
    James M Ferguson
    University of Utah, Salt Lake City, Utah, USA
    Int Clin Psychopharmacol 18:9-14. 2003
    ..The results of the present study provide objective data to support the possibility that reboxetine favourably affects cognitive processes in depressed patients...
  6. ncbi request reprint Citalopram treatment of paroxetine-intolerant depressed patients
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute Clinic, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
    Depress Anxiety 16:128-33. 2002
    ....
  7. ncbi request reprint The antidepressant efficacy of reboxetine in patients with severe depression
    Stuart Montgomery
    Imperial College School of Medicine, London, U K
    J Clin Psychopharmacol 23:45-50. 2003
    ..These results demonstrate that reboxetine is significantly more effective than placebo in a subgroup of patients with severe depression...
  8. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
    ..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
  9. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    J Clin Psychiatry 68:1246-56. 2007
    ..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression...
  10. ncbi request reprint Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder
    Anita H Clayton
    University of Virginia, Department of Psychiatric Medicine, Charlottesville 22903, USA
    Int Clin Psychopharmacol 18:151-6. 2003
    ..These results suggest that reboxetine may be of particular benefit for patients at risk for sexual dysfunction with SSRIs...